臨床研究および検査研究の記録

  • ISSN: 2386-5180
  • ジャーナル h-index: 17
  • 雑誌引用スコア: 6.26
  • ジャーナルのインパクトファクター: 5.31
インデックス付き
  • Genamics JournalSeek
  • 中国国家知識基盤 (CNKI)
  • サイテファクター
  • 研究ジャーナル索引作成ディレクトリ (DRJI)
  • パブロン
  • ユーロパブ
  • Google スカラー
  • シェルパ・ロメオ
  • 秘密検索エンジン研究所
このページをシェアする

抽象的な

Protection of Doxorubicin-Induced Biochemical Injury in the Rat Bone Marrow by a Dietary Bioflavonoid Naringin

Ganesh Chandra Jagetia, Hmingthazuali VL

Doxorubicin is a secondary metabolite isolated, from Streptomyces peucetius and has been used as a standard chemotherapeutic agent alone or in conjunction with other chemotherapeutic drugs to treat different types of malignancies. The use of doxorubicin associated with adverse toxic side effect on bone marrow heart, kidneys and liver in patients receiving its therapy Therefore, any agent that can reduce the toxicity of doxorubicin will be useful in clinical conditions. Naringin a dietary flavonoid synthesized by different citrus fruits has been investigated for its protective effect against the doxorubicin-induced biochemical stress in albino rat bone marrow administered with 2 mg/kg body weight of naringin or 5 mg/kg body weight of doxorubicin either alone or in combination with each other. The bone marrow was aspirated at ½, 1 and 2 h post-doxorubicin treatment and activities of glutathione-s-transferase, catalase and superoxide dismutase, and glutathione concentration and lipid peroxidation were measured. Administration of doxorubicin alone caused a time dependent but significant reduction in the activities of catalase and superoxide dismutase and glutathione concentration followed by increased lipid peroxidation at ½, 1 and 2 h post-doxorubicin treatment. The treatment of rats with naringin before doxorubicin administration significantly raised the activities of catalase and glutathione concentration followed by reduction in the lipid peroxidation in the rat bone marrow. Our study shows that naringin attenuated the doxorubicin-induced biochemical stress and may be a useful agent in reducing the toxicity of doxorubicin in patients.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません